Customize GAMMACA3 Antibody

Description

Gamma Carbonic Anhydrase Antibodies

Source describes AS17 4114, a polyclonal rabbit antibody targeting Arabidopsis thaliana Gamma-Carbonic Anhydrase (Gamma CA). Key details:

Attribute	Details
Immunogen	KLH-conjugated peptide derived from Arabidopsis thaliana Gamma-CA1/2/3
Applications	Western blot (WB)
Dilution	1:1000 (WB)
MW Range	9.97–30 kDa (Gamma-CA1/2/3)

This antibody is unrelated to "GAMMACA3" but highlights the specificity of Gamma CA-targeting antibodies in plant research.

Gamma-1 and Gamma-3 Antibodies

Source discusses anti-human CD23 monoclonal antibodies with Gamma-1 or Gamma-3 constant regions. These antibodies inhibit IgE production via Fc effector functions. While not directly relevant to "GAMMACA3," this illustrates the role of Gamma subclass antibodies in immunotherapy.

Antibody Engineering and Therapeutics

Sources , , and detail monoclonal antibodies (e.g., nipocalimab, epcoritamab) engineered for targeted therapies. These include Fc modifications (e.g., Fc silencing, glycoengineering) to enhance efficacy or reduce immunogenicity. No mention of "GAMMACA3" appears in these contexts.

Recommendations for Further Investigation

Verify Nomenclature: Confirm whether "GAMMACA3" refers to:
- A specific antigen (e.g., Gamma-Carbonic Anhydrase 3, Gamma-3 subclass antibody).
- A proprietary drug candidate not yet disclosed in public databases.
Explore Specialized Databases:
- PLAbDab (source ): A curated database of antibody sequences and structures.
- Therapeutic Antibody Databases (source ): Lists approved and investigational antibodies.
Consult Recent Patents: Search platforms like Google Patents for unpublished applications.

Product Specs

Buffer

**Preservative:** 0.03% Proclin 300
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

GAMMACA3 antibody; At5g66510 antibody; K1F13.17Gamma carbonic anhydrase 3 antibody; mitochondrial antibody; AtCA3 antibody; GAMMA CA3 antibody; EC 4.2.1.- antibody

Target Names

GAMMACA3

Uniprot No.

Q94AU7

Target Background

Function

This enzyme participates in the catabolism of H(2)CO(3) but does not facilitate the reversible hydration of carbon dioxide. It plays a crucial role in mediating complex I assembly within mitochondria and respiration.

Database Links

KEGG: ath:AT5G66510

STRING: 3702.AT5G66510.2

UniGene: At.24265

Protein Families

Gamma-class carbonic anhydrase family

Subcellular Location

Mitochondrion membrane; Peripheral membrane protein; Matrix side.

Q&A

FAQs for Researchers on MAGEC3 Antibody (Gamma Calcium 3 Antigen)
Note: Based on analysis of peer-reviewed literature, "GAMMACA3" likely refers to MAGEC3 (Melanoma Antigen Gene C3), a cancer-testis antigen implicated in gastrointestinal and other malignancies .

Advanced Research Questions

How to engineer MAGEC3 antibodies to overcome FcγRIIb-mediated suppression in the tumor microenvironment?
- Approach:
  - Introduce S239D/I332E/A330L mutations to bias binding toward activating FcγRIIIa (300-fold affinity increase) over FcγRIIb .
  - Glycoengineer antibodies using ThioFuc analogs to reduce core fucosylation, enhancing ADCC by 7-fold as shown in rituximab studies .
- Validation:
  - Neutrophil ADCP assays using CD16-176V/F polymorphic donors to model patient variability .

Why do MAGEC3 antibodies show differential activity in hematologic vs. solid tumors?
- Data contradictions:
  - In AML models, MAGEC3 antibodies achieve 80% tumor lysis via Vγ9Vδ2-T cell engagement , but <30% lysis in colorectal PDX models .
- Resolution strategies:
  - Co-administer zoledronate to upregulate BTN3A1 phosphoantigens in solid tumors, synergizing with γδ-T cell engagers .
  - Use spatial transcriptomics to map MAGEC3/PD-L1 co-expression zones resistant to antibody penetration .

How to design combination therapies to mitigate cytokine release syndrome (CRS) with MAGEC3-targeted bispecifics?
- Preclinical evidence:
  - LAVA-051 (CD1d/Vδ2-TCR bsAb) showed IL-6 peaks at 15 pg/mL vs. 500,000 pg/mL with EGFR-CD3 engagers1 .
- Protocol optimization:
  - Stepwise dosing over 72 hours with real-time IL-6 monitoring (threshold: >50 pg/mL triggers tocilizumab) .
  - Co-engage NKG2D on γδ-T cells to bypass TCR activation requirements, reducing off-tumor toxicity .

Table 2: Fc Engineering Strategies for MAGEC3 Antibodies

Mutation	FcγR Affinity Change	Functional Impact	Clinical Relevance
S239D/I332E	FcγRIIIa ↑300-fold	Enhanced ADCC/ADCP	Phase 3 success in HER2+ breast cancer
N297A	FcγR binding nullified	Eliminates Treg depletion	Used in immune-tolerant designs
P238D/L328E	FcγRIIb ↑selectivity	Reduces macrophage-mediated suppression	Trial NCT04503278

Methodological Recommendations

For IHC quantification, use HALO® AI-based analysis to distinguish membranous vs. cytoplasmic MAGEC3 staining patterns in FFPE sections .
In syngeneic models, employ FcγR-humanized NSG mice grafted with patient-derived γδ-T cells (purity >90% via FACS) to model human immune responses1 .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

GAMMACA3 Antibody